Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014 Fourth Quarter Earnings

  Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014
  Fourth Quarter Earnings

Business Wire

NEW YORK -- April 1, 2014

Forest Laboratories, Inc. (NYSE:FRX), a leading fully integrated, specialty
pharmaceutical company largely focused on the United States market, will
release its Fiscal 2014 Fourth Quarter financial results before the U.S. stock
market opens on Tuesday, April 29, 2014. At 10:00 AM EDT, Forest will host a
conference call to discuss the financial results and relevant company and
industry topics.

The conference call will be webcast live beginning at 10:00 AM EDT on the
Company's website www.FRX.com. Please log on to the website at least fifteen
minutes prior to the conference call as it may be necessary to download
software to access the call. A replay of the conference call will be available
until May 28, 2014 at both websites and also by dialing (800) 283-7928 (US and
Canada) or (402) 220-0866 (international), Conference Call ID # FRXQ414.

About Forest Laboratories and Its Products

Forest Laboratories (NYSE: FRX) is a leading, fully integrated, specialty
pharmaceutical company largely focused on the United States market. The
Company markets a portfolio of branded drug products and develops new
medicines to treat patients suffering from diseases principally in five
therapeutic areas: central nervous system, cardiovascular, gastrointestinal,
respiratory, anti-infective and cystic fibrosis. Our strategy of acquiring
product rights for development and commercialization through licensing,
collaborative partnerships and targeted mergers and acquisitions allows us to
take advantage of attractive late-stage development and commercial
opportunities, thereby managing the risks inherent in drug development. The
Company is headquartered in New York, NY. To learn more, visit www.FRX.com.

This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements involve a
number of risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and launch
of new products, and the risk factors listed from time to time in Forest
Laboratories’ Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and
any subsequent SEC filings. Forest assumes no obligation to update
forward-looking statements contained in this release to reflect new
information or future events or developments.

Contact:

Forest Laboratories, Inc.
Frank J. Murdolo
Vice President - Investor Relations,
1-212-224-6713
investor.relations@frx.com
or
Amanda Kaufman
Senior Manager Corporate Communications and Media Relations,
amanda.kaufman@frx.com
 
Press spacebar to pause and continue. Press esc to stop.